Dashboard
Manage Tickers

PULMPulmatrix, Inc.

Nasdaq pulmatrix.com


$ 2.01 $ -0.10 (-4.68 %)    

Thursday, 05-Sep-2024 14:18:04 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 2
$ 2.00 x 100
-- x --
-- - --
$ 1.55 - $ 2.75
9,120
na
7.3M
$ 0.79
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-30-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-29-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-10-2021 06-30-2021 10-Q
14 05-11-2021 03-31-2021 10-Q
15 03-23-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-07-2020 06-30-2020 10-Q
18 05-14-2020 03-31-2020 10-Q
19 03-26-2020 12-31-2019 10-K
20 11-01-2019 09-30-2019 10-Q
21 08-05-2019 06-30-2019 10-Q
22 05-15-2019 03-31-2019 10-Q
23 02-19-2019 12-31-2018 10-K
24 11-14-2018 09-30-2018 10-Q
25 08-03-2018 06-30-2018 10-Q
26 05-11-2018 03-31-2018 10-Q
27 03-13-2018 12-31-2017 10-K
28 11-09-2017 09-30-2017 10-Q
29 08-04-2017 06-30-2017 10-Q
30 05-05-2017 03-31-2017 10-Q
31 03-10-2017 12-31-2016 10-K
32 11-04-2016 09-30-2016 10-Q
33 08-04-2016 06-30-2016 10-Q
34 05-05-2016 03-31-2016 10-Q
35 03-10-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-14-2015 06-30-2015 10-Q
38 06-10-2015 03-31-2015 10-K
39 02-13-2015 12-31-2014 10-Q
40 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

pulmatrix-q2-2024-revenue-155m-vs-18m-yoy-eps-159-vs-104-yoy
Pulmatrix Q2 2024 Revenue $1.55M Vs $1.8M ...
08/13/2024 13:07:30

Core News & Articles
Pulmatrix Enters Cross License Agreement W...
05/29/2024 12:49:00

pulmatrix-files-for-mixed-shelf-of-upto-95m
Pulmatrix Files For Mixed Shelf Of Upto $95M
05/17/2024 20:08:58

- SEC Filing

pulmatrix-announces-peer-reviewed-publication-headache-the-journal-of-head-and-face-pain-clinical-results-for-its-orally-inhaled-dhe-for-acute-migraine
Pulmatrix Announces Peer-Reviewed Publicat...
05/15/2024 13:31:53

Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intr...

pulmatrix-q1-2024-eps-023-up-from-122-yoy-revenue-5885m-up-from-1499m-yoy
Pulmatrix Q1 2024 EPS $0.23 Up From $(1.22...
05/10/2024 12:08:57

pulmatrix-q4-eps-057-beats-104-estimate-sales-220m-beat-177m-estimate
Pulmatrix Q4 EPS $(0.57) Beats $(1.04) Est...
03/29/2024 03:27:52

Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(1.04) by ...

pulmonx-sees-fy24-revenue-81m-84m
Pulmonx Sees FY24 Revenue $81M-$84M
02/21/2024 22:19:39

pulmatrix-stops-pur1900-phase-2b-study-patient-enrollment-and-closing-study-in-agreement-with-partner-cipla-to-preserve-cash-and-facilitate-strategic-alternatives
Pulmatrix Stops PUR1900 Phase 2B Study Pat...
01/08/2024 14:04:44

Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to ...

pulmatrix-q3-eps-103-beats-105-estimate-sales-175m-miss-186m-estimate
Pulmatrix Q3 EPS $(1.03) Beats $(1.05) Est...
11/09/2023 14:14:16

Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.05) by ...

stocks-that-hit-52-week-lows-on-wednesday
Stocks That Hit 52-Week Lows On Wednesday
10/04/2023 16:01:17

  On Wednesday, 311 stocks hit new 52-week lows.

stocks-that-hit-52-week-lows-on-tuesday
Stocks That Hit 52-Week Lows On Tuesday
09/26/2023 16:04:06

  On Tuesday, 386 stocks made new 52-week lows.

pulmatrix-announces-fda-acceptance-of-ind-application-for-pur3100-to-treat-acute-migraine
Pulmatrix Announces FDA Acceptance Of IND ...
09/19/2023 13:06:27

Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation...

stocks-that-hit-52-week-lows-on-friday
Stocks That Hit 52-Week Lows On Friday
09/08/2023 17:58:01

  Friday's session saw 225 companies set new 52-week lows.

stocks-that-hit-52-week-lows-on-wednesday
Stocks That Hit 52-Week Lows On Wednesday
08/30/2023 17:18:58

  On Wednesday, 59 companies achieved new lows for the year.

stocks-that-hit-52-week-lows-on-tuesday
Stocks That Hit 52-Week Lows On Tuesday
08/29/2023 18:37:27

  On Tuesday, 99 stocks hit new 52-week lows.

pulmatrix-announces-publication-on-physiologically-based-pharmacokinetic-modelling-of-potential-drug-drug-interactions-with-pur1900-orally-inhaled-itraconazole
Pulmatrix Announces Publication On Physiol...
08/23/2023 13:08:01

Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medicati...

hc-wainwright--co-reiterates-buy-on-pulmatrix-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Pulm...
08/15/2023 10:48:58

HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and maintains $10 price target.

pulmatrix-q2-eps-104-up-from-136-yoy-sales-184m-up-from-133m-yoy
Pulmatrix Q2 EPS $(1.04) Up From $(1.36) Y...
08/10/2023 13:14:43

Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.04) per share. This is a 23.53 percent increase over losses of $(1.36)...

pulmatrix-announces-submission-of-ind-application-to-fda-to-initiate-a-phase-2-trial-of-investigational-drug-pur3100-to-treat-acute-migraine
Pulmatrix Announces Submission Of IND Appl...
07/11/2023 13:06:03

Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company develo...

pulmatrix-presents-pur3100-phase-1-data-at-the-american-headache-society-65th-annual-meeting
Pulmatrix Presents PUR3100 Phase 1 Data At...
06/15/2023 13:21:28

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION